Altimmune/$ALT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Altimmune
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
- Ticker
- $ALT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- Gaithersburg, United States
- Website
- altimmune.com
Altimmune Metrics
BasicAdvanced
$383M
-
-$0.73
0.18
-
Price and volume
Market cap
$383M
Beta
0.18
52-week high
$6.44
52-week low
$1.91
Average daily volume
3.7M
Financial strength
Current ratio
26.783
Quick ratio
26.368
Long term debt to equity
0.075
Total debt to equity
0.073
Interest coverage (TTM)
-27.92%
Profitability
EBITDA (TTM)
-98.634
Gross margin (TTM)
-215,138.71%
Net profit margin (TTM)
-296,000.00%
Operating margin (TTM)
-318,493.55%
Management effectiveness
Return on assets (TTM)
-17.20%
Return on equity (TTM)
-28.87%
Valuation
Price to revenue (TTM)
8,040.816
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-3.252
Free cash flow yield (TTM)
-30.75%
Free cash flow per share (TTM)
-0.606
Growth
Revenue change (TTM)
55.00%
Earnings per share change (TTM)
-38.09%
3-year revenue growth (CAGR)
-27.40%
3-year earnings per share growth (CAGR)
-23.62%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Analyst projections of the future price of Altimmune stock.
Bulls say / Bears say
Altimmune started PERFORMA, its registrational Phase 3 MASH trial, in August and reported $519 million in cash and investments at June-end. Management says that balance can fund the MASH trial through completion, helping it reach the next major readout without an immediate raise. (GlobeNewswire, American Banking News)
Pemvidutide met RECLAIM’s primary endpoint, significantly reducing heavy drinking days versus placebo, with positive results on secondary measures that include FDA registrational endpoints. This gives Altimmune a promising clinical and regulatory starting point for a possible alcohol-use-disorder programme. (GlobeNewswire)
In 48-week Phase 2b MASH data, pemvidutide significantly reduced triglycerides and total cholesterol and improved weight, waist circumference and blood pressure. These broader metabolic effects add to the case that the drug could address several drivers of MASH, not just liver fat. (GlobeNewswire)
PERFORMA has only just started, and its 52-week data readout is not expected until 2029. That leaves years for efficacy, safety or enrolment setbacks before the main MASH value driver is tested. (GlobeNewswire)
Management says the $519 million cash balance funds the MASH trial but not a Phase 3 AUD programme, so expanding the pipeline requires outside financing. A partnership could limit dilution, but otherwise Altimmune may need to raise more capital. (Investing.com, GlobeNewswire)
In RECLAIM, nausea was reported in 44% of pemvidutide patients versus 24% on placebo, and five treated patients stopped because of drug-related adverse events versus none on placebo. These small-trial tolerability issues could hurt adherence or complicate dosing in larger AUD studies. (Watcher News, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Upcoming events
No upcoming events
Altimmune News
AllArticlesVideos
Funds containing Altimmune
Fund name | Fund size | $ALT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.